Risk factors
Alto Neuroscience (ANRO) risk factors
Item 1A of every Alto Neuroscience, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors84 risks9 new10 dropped13 reworded
Alto Neuroscience expanded its risk disclosures following securities class action litigation and a larger federal tax loss carryforward of $78.5 million.
Filed Mar 16, 2026 - FY2024 10-K risk factors85 risks
Alto Neuroscience relies on its unproven precision psychiatry platform, clinical trials for pipeline drugs like ALTO-100 and ALTO-101, and extensive patent protections.
Filed Mar 20, 2025